Note: Descriptions are shown in the official language in which they were submitted.
z~
` Combination containing gro-~h factors and
polyelectrolytes
Description
The invention relates to compositions which,
besides at least one polypeptide with the biological
action of fibroblast growth factors (FGF), contain at
least one cationic polyelectrolyte.
Fibroblast growth factors (FGF) which belong to
the class of endogenous peptide growth factors, wer~
originally detected as substances in the brain and
pituitary and isolated therefrom and showed an activity
promoting the growth of fibroblasts. FGFs are known to be
effective angiogenic factors which are responsible, inter
alia, for neovascularisation in wound healing~ More
details on FGFs, including their modification products,
on their isolation and preparation, their structure,
their biological activities and their mechanisms, and on
corresponding medical uses can be found in the
specialist literature which is now wide~ranging. A
comprehensive review is provided, for example, by
A. Baird and P. Bohlen, Fibroblast Growth Factors in:
Peptide Growth Factors and their Receptors I (editors:
M.B. Sporn and A.~. Roberts) Springer Verlag Berlin,
Heidelberg, New York 1990.
Growth factors regarded as suitable according to
the invention are not only the ~classical~ FGFs such as
acidic fibroblast growth factor (aFGF) and basic fibro-
blast growth factor (bFGF) but also all peptides which
essentially display the biological action of FGF.
FGFs in the narrower sense include natural FGFs
especially of bovine and human origin, as well as FGFs
preparPd by recombination. Particularly preferred are
human aFGF and bFGF prepared by recombination. Details on
bovine and human aFGF and bFGF as prepared by recombina-
tion can be found in the following patent documents, for
example: EP 0 228 449, EP 0 24B 819, EP 0 259 953,
EP 0 275 204. FGFs in the wider sense also include
muteins which differ from aFGF and bFGF to a certain
extent in the number and/or sequence of the amino acids
'
2~
- 2 -
without thereby being associated with a substantial
alteration in the action. In addition, the generic term
is to be understood to cover, for example, various forms
of bFGF which differ in their length: they contain 146,
S 153, 154 or lS7 amino-acid residues. Finally, FGFs in the
wider sense also embrace related peptides, some of which
have distinctly different amino-acid sequences but have
the biological action of FGF. The following ?atent
documents may be mentioned by way of example with
reference to the literature: EP 0 148 922, EP 0 226 181,
EP 0 281 822, EP 0 288 307, EP 0 319 052, EP 0 326 90,
and WO 89-12645. The said peptides are comprised bv
"peptides with FGF action" for simplification.
FGFs within the meaning of the invention
furthermore include derivatives of these peptides which
are obtained with stabilising and/or activity-increasing
agents. These are, in particular, forms of aFGF and bFGF
stabilised against acid, which contain as stabilising
agents, for example, glycosaminoglycans such as heoarin,
heparin fragments, heparan sulfate and dermatan sulfate
or glucan sulfates such as dextran sulfate and cyclo-
dextrin sulfate. FGF derivatives of this type are
described, for example, in EP 251 806, ~P 267 015, EP 312
208, EP 345 660, EP 406 856, EP 408 146, WO 89-12464, WO
90-01941 and WO 90-03797.
Preferred for the present invention are FGFs of
human origin and the muteins thereof, especially bFGF.
It is particularly preferred to use human bFGF prepared
by recombination, as described in EP 0 248 819.
It is common to the peptides with FGF action that
they bind specifically to the FGF receptors of the cell
membrane and then display their biological action, for
example in wound healing. These peptide~ are, however,
also bound non-specifically. The result of this binding
is that, for example, bFGF cannot normally he detected in
serum even after injection. For example, bFGF as a basic
protein ~IP = 9.8) is bound to anionic macromolecules
(for example nucleic acid~ and acidic components of the
extracellular matrix (ECM) such aq heparan sulfate - see,
.:
2~g~
-- 3 --
inter alia, Moscatelli et al.: Interaction of basic
fibroblast growth factor with extracellular matrix and
receptors. Lecture at a conference on "The Fibroblast
Growth Factor Family" arranged by The New York Academy of
S Sciences, 1991). This property is described in the
literature and is utilised, inter alia, for the isolation
of FGFs: purification of a- and bFGF by chromatography on
supports which contain bound heparin.
The non-specific binding of the peptides with FGF
action reduces the amount of FGF able to reach the
specific receptor on the cell. In the particular case of
relatively old (chronic) wounds or burn wounds, or when
large ~nounts of necrotic material are present, the non-
specific binding will absorb a large and, at the same
time, unknown portion of the FGF. This is why accurate
dosage of the effective amount of peptides with FGF
action is Lmpossible~ Overdosage of the active substance
is necessary. This means that ~he dosage is also
unreliable beca~se it is unknown how many non-specific
binding sites are present in the particular wound.
Attempts to stabilise bFGF, to reduce its non-
specific binding and to increase its affinity for the
specific receptor have hitherto entailed combining bFGF
with heparin or other sulfated glycans (for example
dextran sulfate~ or sucralfate. However, a~ present~ bFGF
is normally tested without such additives. The only
ancillary substances added are for stability and Lmproved
administration.
The disadvantage of the use of pure bFGF and, to
varying extents, also the said combinations and d~riva
tives comprises the necessity for overdosage of the
active substance and the unreli~bility of dosage because
it is unknown how many non-specific binding sites are
present i~ the particular wound.
The obiect on which the inven~ion was based wa5
therefore to provide a combination of active substances
whose biological activity is unaffected by the non-
specific binding of the peptides wi~h FGF action.
It i~ true that EP O 312 208 proposes employing
~, .
- 4 ~ 2~
gel formers -together with growth factors, preferably
epidermal g-owth factor (EGF), for improved dosage by
means of di~fusion control. However, this measure does
not solve the fundamental problem of the dosage of growth
factors, wh ch results from the variable non-specific
binding.
It has now ~een found that these dosage problems
can be solved ~y additional administration of at least
one cationic polyelectrolyte on administration of pep-
tides ~ith F~F action. It is surprising in this connec-
tion that a'though the cationic polyelectrolytes block
the non-specific binding sites, for example in the ECM,
nevertheless the peptides with FGF action are able to
reach their specific receptors in the cell membrane, and
thus the biological action of FGF is retained.
It ls possible to use, according to the inven-
tion, a number of known cationic polyelectrolytes. It is
common to them that they irreversibly form complexes
under physiological conditions with cell structures which
bind FGF non-specifically. Examples of suitable cationic
polyelectrolytes are polyamines and -imines, as well as
their quaternised derivatives. Also suitable are poly-
guanidines, as well as polypeptides which contain basic
amino acids; for example polylysine, polyornithine,
polyarginine. It is also possible for polypeptides of
these types to contain mixtures of a plurality of amino
acids. The amino acids themselves can be employed either
in racemic for~ or in pure D or L form in the peptides
used according to the invention. Also suitable are
polysaccharides with basic groups. It is parti~ularly
preferred to use chitosans and their derivatives, for
example N-carboxybutylchitosan or methylpyrrolidone-
chitosan, because these are biodegradable and the
degradation products are identical to components of
normal metaboli~m (glucosamine and N-acetylglucosamine).
It is possible according to the invention to
employ the cationic polyelectrolytes as free bases or
else as salts with physiologically tolerated organic or
inorganic acids. Examples of physiologically tolerated
,
': ' '
,.
- 5 -
organic acids are glutamic acid, acidic acid and lacti~
acid~ ~ydrochloric acid is mentioned as example of a
physiologically tolerated inorganic acid. Other physio-
logically tolerated acids are known to the pharmaceutical
techno'ogist.
These substances are administered in excess
compared with the peptides with FGF action and at the
same time as the latter. It is likewise possible to
administer the cationic polyelectrolytes previously. This
results ir. FGFs being able to di~fuse unhindered to the
specific receptor and bind thereto. However, it is also
conceivable within the scope of the procedure according
to the invention to administer the cationic polyelectro-
lytes subsequently in order to displace the FGFs from the
non-specific binding sites. The advantage of this pro-
cedure is the possibility in each case of using a com-
paratively low dose of the peptides with FGF action,
which results in a corresponding increase in the thera-
peutic index. In addition, considerably more reliable use
can be achieved, since the FGFs are able to reach the
target site even in the case of highly necrotic wounds.
Multiple administration is often indicated in such cases.
The invention therefore relates to combinations
which contain at least one polypeptide with FGF action
and at least one cationic polyelectrolyte.
The combinations according to the invention can
in this connection preferably be in the form of aqueous
solutions which, besides at least one polypeptide with
FGF action and at least one cationic polyelectrolyte,
contain customary additives such as buffer substances or
salts to regulate the osmotic pressure or else filler
The concentration of the polypeptides with FGF action in
these solutions is between 0.1 ng/ml and 500 ~g~ml,
preferably between 0.5 ng/ml and 300 ~g/ml, and that of
the cationic polyelectrolytes is between 1 ~g/ml and
300 mg/ml, preferably between 0.1 and 200 mg/ml. These
solutions can be furthex processed in a known manner by
adding gel formers to give hydrogels. The solutions,
where appropriate with added fillers, or hydrogels can be
,. ~ , ,
2~?7~ 2
-- 6
dried or lyophilised to ~ive web materials, to give
films, to give powders, to give granules or to give
threads. Threads obtained in this way can be further
processed to give woven fabrics or nets. It is also
S possible to absorb these solutions in wound gauze or in
wound closure film and to dry the latter. The dried
presentations can also be used, reconstituted with
liquid, as aqueous solution or as gel or hydrogel for
wound dressing. Finally, the combinations according to
the invention can also be in the form of a reagent
assemblage (kit) in which the components (peptide with
FGF action and cationic polyelectrolyte) are present
separately but in balanced amounts.
In the case of fresh, clean wounds, a small
excess of cationic polyelectrolyte, i.e. at least about
five times the amount of peptides with FGF action, is
sufficient for the masking. However, this excess must be
considerably increased appropriate for the state of the
wound in order to block the non-specific binding sites.
For this reason it is possible according to the invention
for the amount of cationic polyelectrolyte to be up to
ten thousand times the amount of the peptide with FGF
action. The ratio between the amounts by weight of
cationic polyelectrolyte and peptide with FGF action is
pre~erably between 100 and 2,000.
The invention furthermore relates to the use of
an addition of at least one cationic polyelectrolyte to
a preparation which contains at least one peptide with
F~F action in order to block non-speciic binding sites
for the peptide with FGF action.
The invention relates to processes for the
preparation o~ ~ombinations which contain at least one
peptide with FGF action and, in addition, at least one
cationic polyelectrolyte, wherein the components are
~5 pre~erably present as aqueous ~olution, and furthermore
can contain customary additives such as buffer substances
or salts to regulate the osmotic pressure or else
fillers. These solutions can also be sterilised. It is
additionally possible to process these solutions further
:.
~ ': ," ~ . ,
_ 7 _
to give semisolid or solid presentations, for example
hydrogels, webs, threads, woven fabrics, granules,
powders, impregnated materials.
The invention relates to processes for the
preparation of pharmaceutical compositions, in which a
combination which contains at least one peptide with FGF
action and, in addition, at least one cationic poly-
electrolyte is converted with at least one solid, liquid
or semiliquid vehicle or ancillary substance into a
suitable dosage form.
The invention relates to pharmaceutical com-
positions which contain combinations composed of at least
one peptide with FGF action and, in addition, at least
one cationic polyelectrolyte.
The invention relates to the use of combinations
which contain at least one peptide with FGF action and,
in addition, at least one cationic polyelectrolyte for
controlling diseases.
The invention relates to the use of a combination
which contains at least one peptide with FGF action and,
in addition, at least one cationic polyelectrolyte for
the preparation of a pharmaceutical.
The combinations according to the invention can
advantageously be employed for the therapy of wounds fo~
which FGF therapy is indicated, especially when free
granulation processes are involved in the healing o~
these wounds or defects. Important areas o~ application
of the combinations according to the invention are ulcers
of the skin (for example pressure sores, diabetic
gangrene, arterial and venous congestion), in addition
wounds from burns, mucosal ulcers and lesions, skin
donation sites, skin and soft-tissue transplantation
sites (preparation of the floor of the wound) and surgi-
cal wounds (especially where healing fun~tions are
impaired). For all these areas o~ application the
administration of combinations of peptides with FGF
action and suitable polycations is particularly
important when the patients' wound-healing capacity is
impaired (for example because o~ age, basic diseases or
- 8 - 2~
therapeutic measures).
Examples
The preparation and use of the combinations
according to the invention is described by way of example
hereinafter, but this descripticn is not to be regarded
as a restriction of the subject-matter of the invention.
The advantages compared with the FGF-containing prepara-
tions known to date from the state of the art become
clear from the reported examples of use.
]0 Example 1
Example la: chitosan solution
100 mg of ~hitosan glutamate (Protan) are dissolved in
10 ml of Ringer's solution.
Example lb: bFGF solution
100 ~g of human bFGF prepared by recombination are
dissolved in 10 ml of 20 mM citrate buffer pH 5Ø
Example lc: combined chitosan-bE~F solution
10 ml each of the solutions from Examples la and lb are
mixed. The final concentration of b~GF is 5 ~g/ml.
Example 2
Example 2a: chitosan solution
100 mg of methylpyrrolidone-chitosan are dissolved in
10 ml of aqueous sodium chloride solution (9 gtl).
Example 2b: bFGF solution
~g of human bFGF prepared by recombination are
dissolved in 10 ml of 20 mM citrate buffer pH 5Ø
_am~a~ combined chitosan-bFGF solution
10 ml each of the solutions from Examples ~a and ~b are
mixed. The final concentration of bFGF is 2.5 ~g/ml.
Example 3
After preparation of the solution from Example lc it is
lyophilised in a layer thickness of 2-5 mm. The result
is a web which contains active substance and is suitable
for covering wounds.
- 9~
Example 4
Commercially available wound dressing gauze is impreg-
nated with a solution from Example 2c (2 ml/5 cm2) and
then dried. The result is a gauze which contains active
substance and is suitable for covering wounds.
Use example A
The viscous solution from Example lc is uniformly applied
at about 1 ml/5 cm2 area of wound to the wound to be
treated.
Use example B
The wound is first pretreated with a solution from
Example la (chitosan) (about 1 ml/5 cm2 area of wound).
After a pretreatment time of about 30 minutes, the excess
solution and wound discharge are removed with a swab. The
wound is subsequently treated further with a solution
from Example lb (bFGF) (about 1 ml/S cm2 area of wound).
Use example C
The wound is first pretreated with a solution from
Example la (chitosan) (about 1 ml/5 cm2 area of wound).
After a pretreatment time of about 30 minutes, the excess
solution and wound discharge are removed with a swab. The
wound is ubsequently treated further with a solution
from Example lc (combination of chitosan and bFGF) (about
1 ml/5 cm2 area of wound).
~5 The latter method has the advantage that the application
of the combination of bF&F and chitosan results in bFGF-
binding substances which have been newly dischaxged into
the area of the wound are absorbed.
: .
:
